Severe sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: A case report

Interleukin (IL)-6 plays an essential role in the pathogenesis of systemic juvenile idiopathic arthritis (sJIA). Tocilizumab (TCZ), a kind of biological agent against both membrane and soluble IL-6 receptor, is the only biological agent approved for the treatment of sJIA in China.